Opko Health Inc (OPK) : During the past 4 weeks, traders have been relatively bearish on Opko Health Inc (OPK), hence the stock is down -1.78% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.26% relative to the S&P 500. The 4-week change in the price of the stock is -1.4% and the stock has fallen -2.29% in the past 1 week.
Opko Health, Inc. has dropped 3.15% during the last 3-month period . Year-to-Date the stock performance stands at -2.19%. The stock has recorded a 20-day Moving Average of 1.59% and the 50-Day Moving Average is 1.03%.
Opko Health Inc (NYSE:OPK): The stock opened at $9.85 on Friday but the bulls could not build on the opening and the stock topped out at $9.88 for the day. The stock traded down to $9.76 during the day, due to lack of any buying support eventually closed down at $9.83 with a loss of -0.30% for the day. The stock had closed at $9.86 on the previous day. The total traded volume was 1,426,215 shares.
Also, Deutsche Bank maintains its rating on Opko Health Inc (NYSE:OPK). The global brokerage major lowers the current price target from $11 per share to $10 per share. Analysts at the Deutsche Bank have a current rating of Hold on the shares. The rating by the firm was issued on June 16, 2016.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.